{"id":47860,"date":"2020-07-31T07:49:58","date_gmt":"2020-07-31T12:49:58","guid":{"rendered":"https:\/\/www.partnershipagainstcancer.ca\/?post_type=topics&#038;p=47860"},"modified":"2023-08-21T13:53:22","modified_gmt":"2023-08-21T18:53:22","slug":"abnormal-call-rates-breast-cancer-screening","status":"publish","type":"topics","link":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/","title":{"rendered":"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein"},"content":{"rendered":"<p>En mati\u00e8re de d\u00e9pistage du cancer du sein, le taux de rappel pour anomalie est le pourcentage de mammographies interpr\u00e9t\u00e9es comme anormales et n\u00e9cessitant donc des examens suppl\u00e9mentaires. Si le TRA est trop faible, un certain nombre de cancers ne seront pas d\u00e9tect\u00e9s; s\u2019il est trop \u00e9lev\u00e9, on demandera \u00e0 certaines personnes de passer des examens de suivi inutiles.<br \/>\n<img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-47966\" src=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1.jpg\" alt=\"woman outside\" width=\"700\" height=\"400\" srcset=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1.jpg 700w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1-300x171.jpg 300w\" sizes=\"auto, (max-width: 700px) 100vw, 700px\" \/><br \/>\nUn TRA id\u00e9al correspond \u00e0 un niveau d\u2019\u00e9quilibre entre ces deux \u00e9cueils. On constate qu\u2019au Canada, les TRA augmentent, dans un contexte o\u00f9 les taux de d\u00e9tection de cancers restent les m\u00eames. Cela signifie que l\u2019on signale davantage de faux positifs, et qu\u2019en cons\u00e9quence, un plus grand nombre de personnes subissent des proc\u00e9dures \u00e9vitables, ayant des r\u00e9percussions sur leur bien-\u00eatre physique et psychologique.<\/p>\n<p>La communaut\u00e9 canadienne du d\u00e9pistage du cancer du sein a \u00e9labor\u00e9, avec le soutien du Partenariat, un <a href=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Framework-for-action-ACR-breast-screening-FR.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">cadre visant \u00e0 atteindre des TRA optimaux<\/a>. Sa mise en \u0153uvre contribuera \u00e0 maintenir les avantages des programmes de d\u00e9pistage, tout en r\u00e9duisant les pr\u00e9judices pour les patientes et les co\u00fbts pour les syst\u00e8mes de sant\u00e9.<\/p>\n<blockquote class=\"blockquote-smaller\"><p>Le pr\u00e9sent Cadre a \u00e9t\u00e9 \u00e9labor\u00e9 en vue de garantir que les personnes subissant un d\u00e9pistage du cancer du sein b\u00e9n\u00e9ficient de pratiques de d\u00e9pistage normalis\u00e9es et de haute qualit\u00e9, qui leur \u00e9vitent de recourir inutilement au syst\u00e8me de sant\u00e9. La COVID-19 accroissant les exigences pesant sur les syst\u00e8mes de sant\u00e9 du Canada, il est essentiel que nous r\u00e9duisions notre utilisation de leurs ressources, tout en maintenant la qualit\u00e9 des soins.<\/p>\n<p><em>&#8211; D<sup>re<\/sup> Nancy Wadden, vice-pr\u00e9sidente, Soci\u00e9t\u00e9 canadienne de l\u2019imagerie mammaire; pr\u00e9sidente, Groupe de travail du Programme d\u2019agr\u00e9ment en mammographie, Association canadienne des radiologistes<\/em><\/p><\/blockquote>\n<h2>Contenu du Cadre<\/h2>\n<p>Il existe de nombreux moyens pratiques d\u2019optimiser les TRA. Le <a href=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Framework-for-action-ACR-breast-screening-FR.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Cadre d\u2019action pancanadien pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein<\/a> propose, pour ce faire, six approches fond\u00e9es sur des donn\u00e9es probantes.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/peer-review-mentorship\/\"><strong>Examen par les pairs, mentorat<\/strong><\/a> et <strong><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/education\/\">formation<\/a><\/strong> : ces approches visent \u00e0 aider les radiologistes \u00e0 am\u00e9liorer leur rendement.<\/li>\n<li><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/standardized-report-cards\/\"><strong>Fiches de rendement normalis\u00e9es<\/strong><\/a> : cette approche vise \u00e0 d\u00e9crire les objectifs d\u2019am\u00e9lioration du rendement des radiologistes et les prochaines \u00e9tapes \u00e0 mettre en \u0153uvre pour les atteindre.<\/li>\n<li><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/minimum-reading-volumes\/\"><strong>Nombre minimal d\u2019interpr\u00e9tations<\/strong><\/a> : cette approche vise \u00e0 doter les radiologistes d\u2019une plus grande exp\u00e9rience en mati\u00e8re d\u2019interpr\u00e9tation.<\/li>\n<li><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/batch-reading\/\"><strong>Interpr\u00e9tation par lots<\/strong><\/a> : cette approche vise \u00e0 permettre aux radiologistes de rester concentr\u00e9s et d\u2019interpr\u00e9ter les mammographies sans \u00eatre interrompus.<\/li>\n<li><a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/double-reading\/\"><strong>Double interpr\u00e9tation<\/strong><\/a> : cette approche repose sur l\u2019interpr\u00e9tation de chaque mammographie par deux personnes.<\/li>\n<\/ul>\n<p>La communaut\u00e9 du d\u00e9pistage du cancer du sein peut favoriser l\u2019obtention de TRA optimaux en introduisant ou en renfor\u00e7ant ces approches dans le cadre de ses programmes de d\u00e9pistage organis\u00e9. Ce faisant, on contribuera \u00e0 maximiser les avantages du d\u00e9pistage organis\u00e9 du cancer du sein pour la population canadienne.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-47963\" src=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Six-circlers-FR.jpg\" alt=\"Icones six approaches\" width=\"1219\" height=\"656\" srcset=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Six-circlers-FR.jpg 1219w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Six-circlers-FR-300x161.jpg 300w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Six-circlers-FR-1024x551.jpg 1024w, https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Six-circlers-FR-768x413.jpg 768w\" sizes=\"auto, (max-width: 1219px) 100vw, 1219px\" \/><\/p>\n<h2>Objectifs du Cadre<\/h2>\n<p>Les six approches du Cadre, s\u2019appuyant sur des examens des donn\u00e9es probantes effectu\u00e9s par le <a href=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/07\/evidence-review-cep.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Centre for Effective Practice<\/a> (en anglais seulement) et par <a href=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/07\/evidence-review-rsi.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Research Sciences International<\/a> (en anglais seulement) s\u2019appliquent \u00e0 diff\u00e9rents \u00e9chelons : praticien, programme et syst\u00e8me. Voici les objectifs g\u00e9n\u00e9raux du Cadre :<\/p>\n<ul>\n<li>Acc\u00e9l\u00e9rer l\u2019adoption des pratiques cliniques exemplaires existantes, fond\u00e9es sur des donn\u00e9es probantes;<\/li>\n<li>Appuyer la mise en \u0153uvre d\u2019approches d\u2019am\u00e9lioration de la qualit\u00e9 pour le d\u00e9pistage du cancer du sein;<\/li>\n<li>Maximiser les avantages et r\u00e9duire au minimum les inconv\u00e9nients du d\u00e9pistage et des \u00e9valuations diagnostiques;<\/li>\n<li>Favoriser le suivi, le respect et l\u2019am\u00e9lioration des cibles nationales canadiennes en mati\u00e8re de TRA.<\/li>\n<\/ul>\n<h2>\u00c0 quel public le Cadre est-il destin\u00e9?<\/h2>\n<p>Le Cadre est notamment destin\u00e9 aux utilisateurs suivants :<\/p>\n<ul>\n<li>Les administrateurs des syst\u00e8mes de sant\u00e9, notamment les responsables des programmes de d\u00e9pistage et des sections d\u2019imagerie diagnostique;<\/li>\n<li>Les professionnels de la sant\u00e9, notamment les radiologistes et les technologues en mammographie;<\/li>\n<li>Les chercheurs et les sp\u00e9cialistes travaillant dans le domaine du d\u00e9pistage du cancer du sein;<\/li>\n<li>Les sp\u00e9cialistes des politiques et les d\u00e9cideurs auxquels il incombe de veiller \u00e0 ce que les initiatives d\u2019am\u00e9lioration de la qualit\u00e9 disposent des ressources dont elles ont besoin.<\/li>\n<\/ul>\n<p>Le Cadre a pour vocation de guider ces diff\u00e9rents utilisateurs dans le choix et dans la personnalisation de diff\u00e9rentes strat\u00e9gies, en fonction de leurs propres besoins et de leurs propres priorit\u00e9s.<\/p>\n<h2>Comment le Cadre contribue-t-il \u00e0 la Strat\u00e9gie?<\/h2>\n<p>Le Cadre apporte une contribution directe \u00e0 la <a href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/cancer-strategy\/\"><em>Strat\u00e9gie canadienne de lutte contre le cancer<\/em><\/a>. Publi\u00e9e en 2019, la <em>Strat\u00e9gie<\/em> appelle les intervenants et les partenaires du syst\u00e8me de lutte contre le cancer \u00e0 en am\u00e9liorer l\u2019\u00e9quit\u00e9 et \u00e0 fournir, de mani\u00e8re durable, des soins de qualit\u00e9. Diagnostiquer le cancer plus rapidement, avec exactitude et \u00e0 un stade plus pr\u00e9coce constitue l\u2019une des huit priorit\u00e9s de la <em>Strat\u00e9gie<\/em>.<\/p>\n<blockquote class=\"blockquote-smaller\"><p>Dans le contexte de la r\u00e9ponse du Canada \u00e0 la pand\u00e9mie de COVID-19, nous devons, maintenant plus que jamais, combler les lacunes existant au sein du syst\u00e8me de lutte contre le cancer, tout en g\u00e9n\u00e9rant des gains d\u2019efficacit\u00e9. Les taux de rappel pour anomalie \u00e9lev\u00e9s pr\u00e9valant dans notre pays, dans le cadre du d\u00e9pistage organis\u00e9 du cancer du sein, constituent un domaine sur lequel nous pouvons agir. Le pr\u00e9sent Cadre fournit aux principaux acteurs des syst\u00e8mes de sant\u00e9 des orientations pour ce faire.<\/p>\n<p><em>-Gregory Doyle, pr\u00e9sident, R\u00e9seau canadien de d\u00e9pistage du cancer du sein<\/em><\/p><\/blockquote>\n<p><strong>Document \u00e0 t\u00e9l\u00e9charger<\/strong><\/p>\n<div class=\"documents col-md-12\"><div>\n                                <i class=\"fas fa-file-pdf document-icon\"><\/i>\n                                <div class=\"document-details\">\n                                    <a href=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Framework-for-action-ACR-breast-screening-FR.pdf\" target=\"_blank\">Cadre d'action pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein<\/a><p class=\"file-information\">Taille du fichier 6 MB<\/p>         <\/div>\n                            <\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>En mati\u00e8re de d\u00e9pistage du cancer du sein, le taux de rappel pour anomalie est le pourcentage de mammographies interpr\u00e9t\u00e9es comme anormales et n\u00e9cessitant donc des examens suppl\u00e9mentaires. Si le TRA est trop faible, un certain nombre de cancers ne seront pas d\u00e9tect\u00e9s; s\u2019il est trop \u00e9lev\u00e9, on demandera \u00e0 certaines personnes de passer des [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":0,"parent":0,"menu_order":0,"template":"","topics_tags":[],"type-of-care":[],"cancer-continuum":[1381],"cancer-system-measurement":[],"dbt-cancer-site":[74],"dbt-risk-factors":[],"dbt-population-characteristics":[],"class_list":["post-47860","topics","type-topics","status-publish","hentry","cancer-continuum-screening","dbt-cancer-site-dbv-breast"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Canadian Partnership Against Cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein - Canadian Partnership Against Cancer\" \/>\n<meta property=\"og:description\" content=\"En mati\u00e8re de d\u00e9pistage du cancer du sein, le taux de rappel pour anomalie est le pourcentage de mammographies interpr\u00e9t\u00e9es comme anormales et n\u00e9cessitant donc des examens suppl\u00e9mentaires. Si le TRA est trop faible, un certain nombre de cancers ne seront pas d\u00e9tect\u00e9s; s\u2019il est trop \u00e9lev\u00e9, on demandera \u00e0 certaines personnes de passer des [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Partnership Against Cancer\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-21T18:53:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@cancerstratca\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/\",\"url\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/\",\"name\":\"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein - Canadian Partnership Against Cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/Woman-on-ACR-cover-700x400-1.jpg\",\"datePublished\":\"2020-07-31T12:49:58+00:00\",\"dateModified\":\"2023-08-21T18:53:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/Woman-on-ACR-cover-700x400-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/wp-content\\\/uploads\\\/2020\\\/08\\\/Woman-on-ACR-cover-700x400-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/fr\\\/topics\\\/abnormal-call-rates-breast-cancer-screening\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Topics\",\"item\":\"https:\\\/\\\/www.partnershipagainstcancer.ca\\\/topics\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/#website\",\"url\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/\",\"name\":\"Canadian Partnership Against Cancer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dev.partnershipagainstcancer.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Canadian Partnership Against Cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/","og_locale":"fr_FR","og_type":"article","og_title":"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein - Canadian Partnership Against Cancer","og_description":"En mati\u00e8re de d\u00e9pistage du cancer du sein, le taux de rappel pour anomalie est le pourcentage de mammographies interpr\u00e9t\u00e9es comme anormales et n\u00e9cessitant donc des examens suppl\u00e9mentaires. Si le TRA est trop faible, un certain nombre de cancers ne seront pas d\u00e9tect\u00e9s; s\u2019il est trop \u00e9lev\u00e9, on demandera \u00e0 certaines personnes de passer des [&hellip;]","og_url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/","og_site_name":"Canadian Partnership Against Cancer","article_publisher":"https:\/\/www.facebook.com\/CanadianPartnershipAgainstCancer\/","article_modified_time":"2023-08-21T18:53:22+00:00","og_image":[{"url":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@cancerstratca","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/","url":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/","name":"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein - Canadian Partnership Against Cancer","isPartOf":{"@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/#primaryimage"},"image":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/#primaryimage"},"thumbnailUrl":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1.jpg","datePublished":"2020-07-31T12:49:58+00:00","dateModified":"2023-08-21T18:53:22+00:00","breadcrumb":{"@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/#primaryimage","url":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1.jpg","contentUrl":"https:\/\/www.partnershipagainstcancer.ca\/wp-content\/uploads\/2020\/08\/Woman-on-ACR-cover-700x400-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.partnershipagainstcancer.ca\/fr\/topics\/abnormal-call-rates-breast-cancer-screening\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Topics","item":"https:\/\/www.partnershipagainstcancer.ca\/topics\/"},{"@type":"ListItem","position":2,"name":"Cadre pour optimiser les taux de rappel pour anomalie dans le d\u00e9pistage du cancer du sein"}]},{"@type":"WebSite","@id":"https:\/\/dev.partnershipagainstcancer.ca\/#website","url":"https:\/\/dev.partnershipagainstcancer.ca\/","name":"Canadian Partnership Against Cancer","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.partnershipagainstcancer.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics\/47860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics"}],"about":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/types\/topics"}],"author":[{"embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/users\/24"}],"wp:attachment":[{"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/media?parent=47860"}],"wp:term":[{"taxonomy":"topics_tags","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/topics_tags?post=47860"},{"taxonomy":"type-of-care","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/type-of-care?post=47860"},{"taxonomy":"cancer-continuum","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-continuum?post=47860"},{"taxonomy":"cancer-system-measurement","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/cancer-system-measurement?post=47860"},{"taxonomy":"dbt-cancer-site","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-cancer-site?post=47860"},{"taxonomy":"dbt-risk-factors","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-risk-factors?post=47860"},{"taxonomy":"dbt-population-characteristics","embeddable":true,"href":"https:\/\/www.partnershipagainstcancer.ca\/fr\/wp-json\/wp\/v2\/dbt-population-characteristics?post=47860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}